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Background: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer characterized by complex aberrant
genomes. A fundamental goal of current studies is to identify those somatic events arising in the variable landscape
of PDA genomes that can be exploited for improved clinical outcomes.
Methods: We used DNA content flow sorting to identify and purify tumor nuclei of PDA samples from 50 patients.
The genome of each sorted sample was profiled by oligonucleotide comparative genomic hybridization and
targeted resequencing of STAG2. Transposon insertions within STAG2 in a KRASG12D-driven genetically engineered
mouse model of PDA were screened by RT-PCR. We then used a tissue microarray to survey STAG2 protein
expression levels in 344 human PDA tumor samples and adjacent tissues. Univariate Kaplan Meier analysis and
multivariate Cox Regression analysis were used to assess the association of STAG2 expression relative to overall
survival and response to adjuvant therapy. Finally, RNAi-based assays with PDA cell lines were used to assess the
potential therapeutic consequence of STAG2 expression in response to 18 therapeutic agents.
Results: STAG2 is targeted by somatic aberrations in a subset (4%) of human PDAs. Transposon-mediated disruption
of STAG2 in a KRASG12D genetically engineered mouse model promotes the development of PDA and its progression
to metastatic disease. There was a statistically significant loss of STAG2 protein expression in human tumor tissue
(Wilcoxon-Rank test) with complete absence of STAG2 staining observed in 15 (4.3%) patients. In univariate Kaplan
Meier analysis nearly complete STAG2 positive staining (>95% of nuclei positive) was associated with a median
survival benefit of 6.41 months (P = 0.031). The survival benefit of adjuvant chemotherapy was only seen in patients
with a STAG2 staining of less than 95% (median survival benefit 7.65 months; P = 0.028). Multivariate Cox Regression
analysis showed that STAG2 is an independent prognostic factor for survival in pancreatic cancer patients. Finally,
we show that RNAi-mediated knockdown of STAG2 selectively sensitizes human PDA cell lines to platinum-based
therapy.
Conclusions: Based on these iterative findings we propose that STAG2 is a clinically significant tumor suppressor in
PDA.Background
A genetic hallmark of pancreatic ductal adenocarcinoma
(PDA) is the presence of somatic KRAS mutations in over
90 to 95% of tumors, the most prevalent being KRASG12D
[1,2]. A fundamental question remains the identification
of somatic aberrations arising in the complex genomic
landscape of PDA that drive the progression of KRAS* Correspondence: mbarrett@tgen.org
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reproduction in any medium, provided the ormutant neoplastic cells in humans in vivo. Furthermore,
of significant interest are those selected aberrations that
create therapeutic vulnerabilities that can be exploited to
advance improved and more personalized care of patients.
The STAG2 gene encodes a subunit of the cohesion com-
plex, which plays an essential role in the proper division
and segregation of chromosomes, a process that is essen-
tial for the maintenance of genome stability and cell sur-
vival [3,4]. Mutations targeting this class of genes have
been studied in model systems, but have been detected in
a relatively small number of somatic tumors arising intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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loss of STAG2 expression have been reported in a subset
of tumors and cell lines, including melanomas, sarcomas,
and glioblastomas [3]. Notably, truncating mutations in
STAG2 have been shown to be one of the most com-
mon genetic lesions in bladder carcinoma [8]. Func-
tional analysis has shown that loss of STAG2 leads to
chromosome missegregation and aneuploidy in human
cell lines and may promote a mutator phenotype [3,4].
The development of a KRASG12D-driven genetically
engineered mouse (GEM) model of PDA has provided
a powerful resource for the study of the events that ac-
celerate tumorigenesis and drive tumor progression in
the pancreas [9]. Strikingly, STAG2 was one of the most
frequent and significant insertion targets reported in a
transposon-mediated screen of the KRASG12D GEM
model of PDA. However, mutations in STAG2 and clin-
ically relevant variations in its protein expression levels
have not been reported to date in human PDA samples
[3,8]. Thus, the clinical significance of STAG2 expres-
sion and its role as a tumor suppressor gene in human
PDA remains to be elucidated.
PDA is a highly lethal cancer that is difficult to mo-
lecularly characterize at the biopsy level due to complex
genomes and heterogeneous cellularity, as cancer cells
represent, on average, only 25% of the cells within the
tumor [10]. The presence of admixtures of non-neoplastic
cells in patient samples can obscure the detection of
somatic aberrations, including mutations, homozygous
deletions, and breakpoints, in biopsies of interest. Further-
more, clinical samples frequently contain multiple neo-
plastic populations that cannot be distinguished by
morphology-based methods [11,12]. In order to investi-
gate whether STAG2 is a tumor suppressor in human
PDA, we used DNA content-based flow cytometry to sort
PDA samples from 50 patients. The genome of each
sorted tumor population was then interrogated for som-
atic mutations and aberrations with oligonucleotide array
comparative genomic hybridization (aCGH) and targeted
resequencing using our established protocols [13]. In this
present study we also sought to confirm the inactivation
of STAG2 in those KRASG12D GEM tumors with trans-
poson insertions within the gene to provide further evi-
dence of a tumor suppressor role in PDA. We then used a
tissue microarray (TMA) to survey STAG2 protein ex-
pression levels in 344 human PDA tumor samples and ad-
jacent tissues. The clinical annotation available for each
tumor represented on the TMA allowed the assessment of
STAG2 expression relative to overall survival and re-
sponses to adjuvant therapy. Finally, given the role of
STAG2 in maintaining genomic stability, we used RNA
interference (RNAi)-based cellular assays with PDA cell
lines to assess the potential therapeutic consequence of
STAG2 expression in response to a panel of 18 currentlyused therapeutic agents. Our results provide evidence for
a clinically relevant tumor suppressor role for STAG2 in
KRAS mutant PDA. These highly iterative findings have
implications for the development of personalized ap-
proaches for patients with PDA.
Methods
Clinical samples
PDA samples were obtained under a Western Institu-
tional Review Board protocol (20040832) for a National
Institutes of Health-funded bio-specimen repository
(NCI P01 grant CA109552) and two American Associ-
ation for Cancer Research/Stand up to Cancer (SU2C)
sponsored clinical trials, 20206-001 and 2026-003. Add-
itional PDA samples were obtained with approved
consent of the Ethics Committee of Basel (252/08, 302/09).
All patients in this study gave informed consent for col-
lection and use of all the samples, which were collected
in liquid nitrogen and stored at -80°C. All tumor sam-
ples were histopathologically evaluated prior to gen-
omic analysis. All research conformed to the Helsinki
Declaration [14].
Flow cytometry
Biopsies were minced in the presence of NST buffer and
DAPI according to published protocols [11,15,16]. Nu-
clei were disaggregated then filtered through a 40 μm
mesh prior to flow sorting with an Influx cytometer
(Becton-Dickinson, San Jose, CA, USA) with ultraviolet
excitation and DAPI emission collected at >450 nm.
DNA content and cell cycle were analyzed using the
software program MultiCycle (Phoenix Flow Systems,
San Diego, CA, USA).
aCGH
DNAs were extracted using QIAGEN micro kits (Valencia,
CA, USA). For each hybridization, 100 ng of genomic
DNA from each sample and of pooled commercial
46XX reference (Promega, Madison, WI, USA were
amplified using the GenomiPhi amplification kit (GE
Healthcare, Piscataway, NJ, USA). Subsequently, 1 μg of
amplified sample and 1 μg of amplified reference tem-
plate were digested with DNaseI then labeled with Cy-5
dUTP and Cy-3 dUTP, respectively, using a BioPrime
labeling kit (Invitrogen, Carlsbad, CA, USA). All label-
ing reactions were assessed using a Nanodrop assay
(Nanodrop, Wilmington, DE, USA) prior to mixing and
hybridization to CGH arrays with either 244,000 or
400,000 oligonucleotide features (Agilent Technologies,
Santa Clara, CA, USA). The aCGH data have been de-
posited in the National Center for Biotechnology Infor-
mation (NCBI) Gene Expression Omnibus (accession
numbers GSE54328 and GSE21660).
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For each sequencing reaction 50 ng of DNA was ampli-
fied in 10 μl reactions for 35 cycles using MyTaq™
HSMix (Bioline, Taunton, MA, USA). All PCR products
were verified by visual inspection on agarose gels. Sam-
ples were then purified by column filtration prior to
analysis with an Applied Biosystems 3730 capillary se-
quencer (Life Technologies, Carlsbad, CA, USA). We
surveyed 33 of the 35 exons in STAG2 using published
primers [3]. All sequences were analyzed using Mutation
Surveyor v4.0.5 (Softgenetics, State College, PA, USA).
KRAS mutational status was determined using custom
primers designed to flank, amplify and sequence codons
12, 13 and 61 in exons 2 and 3 of the KRAS gene (Caris
MPI, Irving, TX, USA) [17]. The STAG2 resequencing
data have been deposited in the NCBI BankIt (ID
1699484).
Clinical patient samples, immunohistochemistry, and
tissue microarray analysis
Tissue microarrays of 459 patients with 344 patients eli-
gible for analysis were prepared from patient samples
obtained after appropriate informed consent in Dresden
(Institute of Pathology, University Hospital Dresden),
Regensburg (Institute of Pathology, University Hospital
Regensburg) and Jena (Institute of Pathology, University
Hospital Jena). All samples were obtained with approved
consent of the ethics committee of the Technischen
Universität Dresden. Samples were collected consecu-
tively from patients undergoing routine surgery for pan-
creatic carcinoma. Histological diagnosis was performed
in the individual centers by pathologists trained in the
routine work-up of pancreatic cancer specimens. The
tumor samples were collected from 1993 to 2010, and
most of the patients (68%) did not undergo adjuvant
chemotherapy. Those that did undergo adjuvant therapy
(32%) were chiefly treated with 5-fluorouracil (5-FU) or
gemcitabine-based regimens and received a survival
benefit of median 5.5 months (P = 0.02). The median
survival times of patients after surgery from each center
were indistinguishable. Immunohistochemistry was per-
formed on 5 μm sections that were prepared using
silanized slides (Menzel Gläser, Braunschweig, Lower
Saxony, Germany). Staining was performed manually. In
brief, sections were treated in PTM buffer pH6.0 for
45 minutes in the pressure cooker. After blocking of the
endogenous peroxidase, the sections were incubated
with the STAG2 antibody sc-81852 (1:400 for 30 minutes
at room temperature). Antibody binding was detected
using the Ultravision LP detection System (Thermo
Fisher Scientific, Fremont, CA, USA) and Bright DAB
(Medac, Wedel, Germany). Slides were counterstained
with hematoxylin. Staining of STAG2 immunohisto-
chemistry was performed by one (CP) and checked byanother scientist (DA) with random point controls.
Staining intensities were scored as the percentage of
stained nuclei independent of staining intensity. Samples
with a minimal staining of less than 30% on nuclei were
scored as negative.
Insertional mutagenesis screen
The generation and characterization of the KCTSB13
cohort, and the common insertion sites (CISs) analysis is
described in [9].
Detection of STAG2-T2/Onc fusion mRNA by RT-PCR in
Sleeping Beauty tumors
Total RNA was extracted from snap-frozen pancreatic tu-
mors developed in KCTSB13 mice using the RNeasy Mini
kit (QIAGEN), and total RNA (1 μg) was reverse tran-
scribed into cDNA using the High Capacity RNA-to-
cDNA kit (Applied Biosystems). RT-PCR was carried out
with a nested PCR approach using primers of mouse
STAG2 exon 1 and the carp β-actin splice acceptor se-
quence of the T2/Onc transposon cassette. cDNA was
used as a template in a first round of PCR using specific
primers corresponding to exon 1 of STAG2 (5′-GAGG-
GAACAACATTCATGTG-3′) and the carp β-actin splice
acceptor sequence (5′-CATACCGGCTACGTTGCTAA-
3′). The product of this reaction was used as a template in
a second round of nested PCR using an internal primer in
the STAG2 exon 1 (5′-CCCTCGGCTTCTCTCCCCCG-
3′) and a second primer in the carp β-actin splice acceptor
sequence (5′-ACGTTGCTAACAACCAGTGC-3′). PCR
products were cloned into pCR 2.1-TOPO vector (Invitro-
gen) and positives clones sequenced.
Cell culture
The 13 pancreatic and 3 control cell lines in this study
were obtained directly from ATCC, which performs cell
line characterizations using short tandem repeat profil-
ing [18], and passaged for fewer than 6 months after re-
suscitation. Cells were maintained in RPMI medium
(Invitrogen) supplemented with 10% fetal bovine serum
(FBS) and penicillin/streptomycin (Invitrogen), and pas-
saged for 3 months for all assays.
Western blot analysis
The 13 PDA cell lines and 3 control cell lines (SK-ES-1,
U87-MG, and A375) were lysed in buffer (Roche,
Indianapolis, IN) containing protease and phosphatase
inhibitors. Total protein (25 μg per sample) from each
cell line was resolved on NuPAGE Novex 4-12% Bis-Tris
precast gels (Invitrogen) then transferred to PVDF
membranes. Antibodies against β-actin (Cell Signaling
Technology, Danvers, MA, USA) and STAG2 (Santa
Cruz Biotechnology, sc-81852, Santa Cruz, CA, USA)
were used at 1:30,000 and 1:100 dilutions, respectively.
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agent (GE Healthcare) was used to detect antibody bind-
ing on a BioSpectrum Imaging System (UVP, Upland,
CA, USA).
Small interfering RNA
The pancreatic cancer cell lines PANC-1 and Panc 04.03
were reverse transfected with four small interfering RNA
(siRNA) sequences (QIAGEN) targeting STAG2, in
addition to GFP, UBB, and ACDC control siRNAs (QIA-
GEN). siRNA (1 μl of 0.667 μM) was printed into each
well of barcoded 384-well plates with a solid-white bot-
tom (Corning 8749, Corning, NY, USA) using a Biomek
FX Laboratory Automation Workstation (Beckman
Coulter, Indianapolis, IN, USA). A transfection reagent,
SilentFect lipid (Bio-Rad, Hercules, CA, USA), was used
to introduce the siRNA sequences into the cells. A mix-
ture of SilentFect and serum-free RPMI medium was
added to the plates (20 μl per well) using a BioTek μFill
Dispenser (BioTek, Winooski, VT, USA). Plates were
then incubated for 30 minutes at room temperature to
allow the formation of transfection reagent-nucleic acid
complexes. Cells were trypsinized, quantified and resus-
pended in 10% FBS-RPMI assay medium and dispensed
into the plates (20 μl per well) containing the siRNA
using a μFill Dispenser (1,000 cells per well for PANC-1,
2,000 cells per well for Panc 04.03). Cells were incubated
at 37°C for 24 hours before treatment with varying con-
centrations of each of 18 drugs (ranging from 0.6 nM to
100 μM) currently in use in our clinical trials, or vehicle
alone in medium with 5% FBS by dispensing a 10 μl vol-
ume per well. The plates were further incubated at 37°C
for 5 days before cellular viability was measured using
CellTiter-Glo luminescent reagent (Promega) and an
Analyst GT Multimode Microplate Reader (Molecular
Devices, Sunnyvale, CA, USA). The final assay volume
(per well) contained a 13 nM concentration of each
siRNA, 40 nl of SilentFect transfection reagent and 5%
FBS (20 μl serum-free medium + 20 μl of medium with
10% FBS + 10 μl of drug solution prepared in medium
with 5% FBS).
Results
Rapid autopsy samples, consisting of patient-matched
primary and distant metastatic tissues, have been used
to study the clonal evolution of PDA [13,19]. In our
studies we have screened multiple examples of these tu-
mors using our flow sorting methods to identify clonal
populations of PDA cells for genome analysis. In one of
these cases we detected a 42.5 kb homozygous deletion
in STAG2 in a 4.5 N population sorted from the primary
pancreatic tissue (Figure 1). The clonal deletion mapped
to the 5′ region of the gene and included exon 1 and a
series of regulatory regions [20]. Our use of flow sortedsamples allowed objective discrimination of homozygous
loss with a rigorous threshold of log2ratio < -3.0 in our
aCGH results. The same homozygous deletion was de-
tected in the 4.5 N aneuploid populations found in the
two distinct distant metastatic sites surveyed within the
same patient. In contrast, the patient-matched sorted
diploid population had a normal aCGH profile with an
intact STAG2 locus. The presence of the same somatic
homozygous deletion within a 4.5 N PDA population in
each anatomical site suggests that cells that lost STAG2
arose early in the history of this tumor and contributed
to its progression to metastatic disease. Tumor suppres-
sor genes targeted by homozygous deletions are fre-
quently inactivated by alternative mechanisms, including
somatic mutations [21,22]. Given the role of chromo-
somal instability and aneuploidy in the development and
progression of PDA, we hypothesized that STAG2 would
be somatically deficient in a subset of PDA patients.
To identify somatic mutations we sequenced the first
33 of the 35 STAG2 exons in 50 flow sorted clinical
samples. Tissue samples were obtained from three
sources. The first was a phase II trial of patients with
advanced metastatic disease that had progressed on at
least one prior therapy. The second was a phase III trial
of patients with resectable PDA. The final source was a
tumor bank that included tissues from a series of rapid
autopsy samples. Whenever possible we used a patient
matched blood sample as a control. However, for those
samples of interest without matching normal tissue
samples we evaluated the flow cytometry and aCGH
profiles of the diploid and aneuploid fractions in each
biopsy. In all cases the aneuploid fractions represent
pure (>95%) tumor populations as determined by their
separation from other peaks in the histograms and the
presence of distinct genomic copy number aberrations,
including homozygous deletions (log2ratios < -3.0) and
focal amplicons. In contrast, the total diploid fractions
from PDA biopsies may contain admixtures of neoplas-
tic and non-neoplastic cells. Thus, for each sample of
interest we profiled the total diploid fraction by aCGH.
In all cases the genomes of the sorted diploid cells were
non-aberrant by copy number analysis. This allowed
discrimination of germ line from somatic events for
tumor samples of interest, including those tissues with-
out matching blood samples. A non-conserved STAG2
mutation, E20Q, was found in one additional patient
sample (Figure 2). The somatic nature of this mutation
was confirmed by sequencing the 2.0 N population
sorted from the primary tumor sample. These data pro-
vide the first report of STAG2 somatic aberrations in
human PDA. In addition we detected six recurring pre-
viously reported polymorphisms, and one novel poly-
morphism, throughout the gene in multiple patient


















Figure 1 Homozygous deletion of STAG2 in metastatic PDA. A 4.5 N aneuploid population was detected and sorted in biopsies from the
(A) primary and (B,C) two metastatic sites from rapid autopsy specimen UNMC 12R. (D) aCGH analysis of the sorted diploid (2.0 N; bottom) and
the sorted 4.5 N (top) populations. Chromosome Xq25 CGH plots of (E) sorted 2.0 N population and (F) clonal homozygous deletion of STAG2 in
the 4.5 N populations sorted from the pancreas (top panel), omentum (middle panel), and lung (bottom panel). Shaded areas in (E,F) denote
ADM2 step gram defined genomic intervals.
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tional screen of a pancreatic ductal preneoplasia mouse
model identified a series of genes whose targeted inacti-
vation cooperated with KRASG12D in the development
and progression of PDA [9]. Strikingly, STAG2 was iden-
tified as one of the top 20 candidate genes. Transposon
insertions within the STAG2 locus were found in 37/198
(18.7%) tumors that arose in the mouse model. In this
present study we confirmed that STAG2 expression was
disrupted in these tumors by isolating chimeric fusion
mRNAs that spliced the STAG2 transcript to the T2/
Onc transposon (Additional file 2). The insertions were
found in preinvasive lesions and primary tumors, sug-
gesting that early inactivation of the gene could be im-
portant in the progression of the disease. Insertions were
also found in eight mice with metastasis. This included
one animal with sufficient tumor tissue available for
resequencing from primary and multiple metastases that
confirmed the clonal nature of the STAG2 insertion.
Interestingly, the insertions are found in both males andfemales, suggesting that X-inactivation or haploinsuffi-
ciency could be contributing to the loss of STAG2 ex-
pression in the females.
To further assess the clinical significance of STAG2
expression in human tumors, we screened a TMA con-
taining a collection of 344 specimens obtained from
resected German patients (Additional file 3). In normal
tissue nearly all ductal cells stained with a high intensity
(Figure 3). There was a broad range of signal intensities
with a statistically significant loss of STAG2 expression
in the tumor tissue (Wilcoxon rank test) and complete
absence of STAG2 staining observed in 15 (4.3%) pa-
tients (Additional files 4 and 5). In univariate Kaplan-
Meier analysis nearly complete STAG2-positive staining
(>95% of nuclei positive) was associated with a median
survival benefit of 6.41 months (P = 0.031) (Figure 4).
Interestingly, the survival benefit of adjuvant chemother-
apy can only be identified in the group of patients with
a STAG2 staining <95% (median survival benefit
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Figure 2 Somatic mutation of STAG2 in metastatic PDA. (A) Flow cytometry analysis and sorting of a 3.2 N aneuploid population in primary
pancreas tissue from rapid autopsy specimen UNMC 11R. (B) Whole genome aCGH plot of the 3.2 N population. (C) Detection of somatic
mutation in forward (3.2 N-F) and reverse (3.2 N-R) sequences in the 3.2 N genome. Mutation was not detected in the matching 2.0 N population
sorted from the same tissue.
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ent prognostic factor for survival in pancreatic cancer
patients (Table 1).
Given the role of STAG2 in the maintenance of gen-
omic stability, we hypothesized that loss of STAG2
would create a synthetic lethal condition to exposure to
one or more therapeutic agents. To test this we screened
13 PDA cell lines for expression of STAG2 by western
blot analysis (Additional file 6). These included five cell
lines previously reported as wild type [3]. All 13 cell
lines have been shown to express STAG2 mRNA; how-
ever, 2 of the cell lines had decreased protein levels rela-
tive to the other cell lines (Additional file 7) [23]. We
selected a cell line (PANC-1) positive for STAG2 protein
expression and one cell line (Panc 04.03) with low
STAG2 protein expression for siRNA assays. Each of
these two cell lines was exposed to 8 concentrations of
the 18 clinical drugs available from our recently com-
pleted clinical trial in the presence or absence of 4 siR-
NAs targeting STAG2 (Figure 6). Depletion of STAG2
did not affect the viability of these cell lines in theabsence of drug. The STAG2-positive PANC-1 cell line
displayed an increased sensitivity to the three platinum-
based drugs (cisplatin, carboplatin, oxaliplatin) used in
our assays in the presence of STAG2 targeting siRNAs.
For example, each of the four STAG2 siRNAs signifi-
cantly increased (P < 0.01) the sensitivity of PANC-1
cells to oxaliplatin at drug concentrations of 3.7, and
11.1 μM when compared to GFP control. In contrast,
there was no difference in the response of the low
STAG2 protein-expressing Panc 04.03 cells in the pres-
ence of any of the siRNAs. The knockdown of STAG2 in
PANC-1 and Panc 04.03 cells was confirmed by western
blot analysis for each of the siRNAs.
Discussion
Somatic mutations in STAG2 have now been reported in
a variety of human cancers [3,8,24]. One notable excep-
tion to date has been pancreatic tumors. The initial
analysis of STAG2 in PDA was limited to five established
cell lines [3]. These same cell lines were also positive
for STAG2 protein expression in our current study
Figure 3 Immunohistochemical staining of STAG2 in pancreatic cancer. Near ubiquitous staining in (A) ductal cells of normal tissue, (B) the
primary cancer cell line PaCaDD161, and (D) pancreatic cancer. (C) The cell line PaCaDD135 displays a heterogeneous staining pattern, whereas
in (E) a minor fraction of pancreatic cancer STAG2 expression is lost. Magnification 200× (insets 100×).
STAG2 protein expression 
p = 0.031 











































Figure 4 STAG2 expression and overall survival in patients with PDA. Tissue microarray (TMA) analysis of STAG2 protein expression in PDA
samples from 344 patients. Cumulative survival (y-axis) of patients with intact versus deficient STAG2 expression levels is plotted versus time
(x-axis). Mo, months.















































Figure 5 STAG2 expression and response to adjuvant therapy. Cumulative survival (y-axis) plotted versus time (x-axis) is compared for the
229 STAG2-deficient patients who received (n = 61) or did not receive (n = 168) adjuvant chemotherapy. Mo, months.
Table 1 Multivariate analysis of tissue microarray cohort
Model Variable P-value Hazard ratio
(95% CI)
A. Clinical pathology and STAG2 STAG2 (< 95%) 0.017 1.421 (1.064-1.898)
T stage (1/2) 0.729 1.066 (0.743-1.529)
N stage (N0) 0.196 0.826 (0.618-1.104)
Grade (1/2) 0.013 0.711 (0.544-0.93)
Sex (female) 0.865 1.023 (0.785-1.333)
Margin involvement (negative) 0.297 0.852 (0.63-1.151)
M stage (M0) 0.132 1.487 (0.887-2.492)
B. Clinical pathology and STAG2 STAG2 (< 95%) 0.017 1.415 (1.064-1.883)
T stage (1/2) 0.719 1.068 (0.746-1.531)
N stage (N0) 0.195 0.825 (0.618-1.103)
Grade (1/2) 0.013 0.713 (0.546-0.931)
Margin involvement (negative) 0.3 0.853 (0.631-1.152)
M stage (M0) 0.126 1.494 (0.894-2.497)
C. Clinical pathology and STAG2 STAG2 (< 95%) 0.016 1.42 (1.068-1.888)
N stage (N0) 0.198 0.827 (0.619-1.105)
Grade (1/2) 0.014 0.717 (0.55-0.934)
Margin involvement (negative) 0.321 0.861 (0.64-1.158)
M stage (M0) 0.131 1.484 (0.889-2.478)
D. Clinical pathology and STAG2 STAG2 (< 95%) 0.014 1.428 (1.074-1.898)
N stage (N0) 0.185 0.822 (0.616-1.098)
Grade (1/2) 0.011 0.709 (0.545-0.924)
M stage (M0) 0.086 1.556 (0.94-2.574)
E. Clinical pathology and STAG2 (final model) STAG2 (< 95%) 0.021 1.394 (1.051-1.849)
Grade (1/2) 0.007 0.697 (0.536-0.906)
M stage (M0) 0.061 1.615 (0.979-2.665)
CI, confidence interval.



















* * * * ** * *
Figure 6 Synthetic lethal analysis of STAG2 knockdown and exposure to chemotherapeutic agents in PDA cells. (A) Synthetic lethal
response of PANC-1 cells and (B) Panc 04.03 cells in the presence of oxaliplatin. (C) Absence of response of PANC-1 cells in the presence of
gemcitabine. Asterisks indicate that all four siRNA sequences at drug concentrations of 3.7 and 11.1 μM have P < 0.01 when compared to GFP
control. Error bars in (A-C) represent standard deviations. (D) Western blot of STAG2 expression in PANC1 cells in the presence of control (GFP)
and four STAG2 siRNAs. (E) Drugs used in siRNA synthetic lethal screen.
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sequencing-based studies of the genomic landscape of
PDA tumors have not detected somatic aberrations that
selectively disrupted the STAG2 locus [1,25]. Thus, to
our knowledge, this report represents the first descrip-
tion of a tumor suppressor role for STAG2 in human
PDA. A key feature of our study of human tumors is the
use of DNA content flow assays to identify and purify
distinct populations of tumor cells in each biopsy of
interest. These assays enable an unbiased analysis of
clinical human PDA tissues regardless of tumor content.
For example, in the two confirmed cases of somatic
genomic targeting of STAG2 the tumor cell content was
less than 10% of the total cellular content of the biopsy
(Figures 1 and 2). Our use of highly purified flow sorted
tumor populations and the ability to detect homozygous
deletions and mutations in PDA clinical samples, regard-
less of cellularity and tumor content, provides a robust
screen for potential tumor suppressors.
Recent cancer genome studies have identified multiple
examples of mutations and aberrations of potential
driver genes in relatively small subsets (1 to 5%) of pa-
tients with a given tumor type [26-28]. Strikingly, manyof these low frequency driver events occur in multiple
tumor types, highlighting their potential clinical signifi-
cance. Notably, a STAG2 mutation was identified as a
driver of clonal evolution from myeloid dysplastic syn-
drome to secondary acute myeloid leukemia [24]. The
relatively low prevalence of STAG2 somatic aberrations
that we report in PDA is consistent with those in many
other tumors [21]. The identification of STAG2 as one
of the most significant tumor suppressors of KRASG12D-
driven PDA in the GEM model supports an interactive
role of these two genes in the development and progres-
sion of PDA. In our studies of human PDA we have con-
firmed the presence of KRAS mutations in over 95% of
the flow sorted samples we have profiled. These include
the two patients with STAG2 somatic aberrations in the
current study, one of whom had a clonal homozygous
deletion in the primary tumor and two distant metastatic
lesions. Thus, our current results further support the
findings from the mouse model that STAG2 inactivation
cooperates with KRAS mutation as an early event in the
evolution and progression of human PDA.
Our TMA-based expression analysis provides further
clinical validation of a tumor suppressor role for STAG2
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bladder cancer included an immunohistochemistry
screen across a broad panel of tumor types [8]. These in-
cluded 36 PDA tumors, none of which showed loss of
STAG2 expression. Tumor suppressor genes that are lo-
cated on chromosome X are frequently subject to epi-
genetic regulation and silencing by chromosome X
inactivation [29,30]. The reactivation of silent but intact
copies of these tumor suppressors with agents such as 5-
aza-2′-deoxycytidine and histone deacetylase (HDAC)
inhibitors such as trichostatin has been proposed as a
strategy to enhance therapeutic responses in solid tu-
mors. The number of tumors (4.3%, 15/344) with a
complete absence of protein expression in our panel of
primary surgical resection tissues and our finding of
somatic genetic lesions in 4% (2/50) of tumors surveyed
reflects the overall prevalence of those PDAs with
complete STAG2 loss (Additional file 8). However, a
striking finding was the effect of even modest decreases
of STAG2 protein levels on survival and response to ad-
juvant therapies (Figures 4 and 5). The presence of intact
but under-expressed copies of this mediator of genome
stability provides a potential therapeutic vulnerability
similar to that proposed for the X-linked deubiquitinase
USP9X [9]. Specifically, up-regulation of deficient but in-
tact STAG2 may provide a therapeutic benefit for pa-
tients with PDA, including those who have already
progressed to invasive stages of disease. Furthermore,
given the synergistic interaction with KRAS mutations,
an early and ubiquitous genetic event in the develop-
ment of PDA and the clinical significance of deficient
expression, development of agents that increase STAG2
expression may provide a strategy for both treatment
and prevention. However, a caveat for this approach is
that, unlike USP9X, there is a low (approximately 4%)
but potentially significant prevalence of genetic lesions
in STAG2 in human PDA.
Current therapeutic options for patients with advanced
PDA include a series of chemotherapeutics with a broad
range of mechanisms and targets (Figure 6). STAG2 has
been shown to regulate proper chromosome segregation
in diploid cells. Loss of function gives rise to chromo-
some aneuploidy and a mutator phenotype in model sys-
tems. Thus, we hypothesized inactivation of STAG2
could create a synthetic lethal combination with one or
more currently used therapeutic agents that target either
DNA replication or repair. Consistent with this, our
TMA-based analysis of localized surgically resected tu-
mors showed that those PDAs with deficient STAG2
levels derived the most benefit from standard adjuvant
therapy with either gemcitabine or 5-FU. Our finding
that RNAi-based silencing of STAG2 sensitizes PDA cells
specifically to platinum-based therapies in vitro suggests
that the increased therapeutic benefit seen in patientsreceiving adjuvant therapies could be further enhanced.
However, it remains to be determined if this added bene-
fit may be limited to those relatively rare PDAs with
complete loss of STAG2 expression.Conclusions
The clinical significance and translational importance of
low frequency mutations and genomic lesions is a chal-
lenge to the study of PDA and other solid tumors. Our
iterative approach, involving clonal genomic analysis of
clinical samples, genetically engineered mouse models,
clinical validation of genes of interest, and functional in-
terrogation of candidate therapeutic targets and agents
provides a comprehensive and highly translational ap-
proach to the study of PDA. This current work validates
that STAG2 behaves as a tumor suppressor gene in hu-
man PDA. Given its role in the maintenance of genome
stability, the synergy with KRAS mutations, and the clin-
ical significance of altered expression, we propose that
deficiencies in STAG2 represent a potential therapeutic
vulnerability that can be exploited for improved treat-
ment and possible prevention of PDA.Additional files
Additional file 1: Table S1. STAG2 SNPs detected in flow sorted PDA
tissue samples.
Additional file 2: Figure S1. Transposon insertion sites within the
STAG2 locus. STAG2 was inactivated by insertional mutagenesis in a
screen to identify genes that cooperate with K-RasG12D in the
development of pancreatic cancer (Perez-Mancera et al. [9]). Isolation of
the transposon insertion sites from 198 pancreatic tumor samples from
the KCTSB13 cohort revealed a common insertion site in STAG2 in 18.6%
of tumors, supporting its role as tumor suppressor gene in pancreatic
cancer development. Transposon insertions parallel to STAG2 expression
are shown in green, while antiparallel insertions are shown in red. The
lower panel shows the STAG2 exon 1-T2/Onc chimeric mRNA in one of
the tumors, confirming its inactivation by the transposon.
Additional file 3: Table S2. Patient characteristics and TMA cohort.
Clinical and histological parameters were used to calculate P-values with
Kaplan-Meier statistics log-rank test. OS, overall survival. Daggers indicate
the comparison of M0 versus M1 without the cases with Mx. Bold
indicates P-values <0.05.
Additional file 4: Figure S2. Distribution of STAG2 staining across 344
PDA samples. A histogram analysis of percentage STAG2 staining from
TMA analysis in PDA patients.
Additional file 5: Figure S3. Immunohistochemical staining of STAG2 in
pancreatic cancer. (A-C) Negative staining indicating loss of STAG2
expression in pancreatic cancers. The staining pattern is heterogeneous.
(D) In a fraction of pancreatic cancer cells, however, STAG2 expression is
lost and the surrounding stromal tissue displays no STAG2 staining.
Magnification 130× in (A,B,D) (60×).
Additional file 6: Figure S4. Western blot analysis of STAG2 expression
in pancreatic cancer cell lines. Antibodies against β-actin (Cell Signaling
Technology) and STAG2 (Santa Cruz Biotechnology,
sc-81852) were used at 1:10,000 and 1:200 dilutions, respectively, against
20 μg of total protein from each of 13 pancreas and 3 control cell lines.
Exposure times (60 minutes for STAG2 and 30 seconds for β-actin) were
adjusted to account for the high and low molecular weights of the
proteins and their differential signal intensities.
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http://genomemedicine.com/content/6/1/9Additional file 7: Figure S5. STAG2 RNA expression in pancreatic cell
lines. Box plot summary of gene expression RNA levels for 1,000 cell lines
in Cancer Cell Line Encyclopedia (CCLE). The summary includes 44
pancreas cancer cell lines.
Additional file 8: Figure S6. Survival time of STAG2-null (0%,
n = 15) and STAG2-expressing (>0%, n = 329) PDA tumors.
Kaplan-Meier curve of the 15 completely negative tumors versus the
329 tumors with varying degrees of positive staining.
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